Atrium Therapeutics, Inc. has issued an amended SEC filing to correct the number of shares outstanding after a recent securities offering. This amendment is crucial for maintaining transparency and accuracy in the company's financial reporting, which is essential for investor confidence.
The amendment, filed on October 9, 2026, serves as a follow-up to the original filing made on October 8, 2026. The company disclosed that it entered into a securities purchase agreement with accredited investors to sell 5,170,384 shares of its common stock and pre-funded warrants for an additional 1,134,930 shares. Following this offering, Atrium Therapeutics will have a total of 21,571,507 shares of common stock outstanding.
Background
Atrium Therapeutics, Inc. operates in the pharmaceutical preparations industry, specifically categorized under SIC 2834. The company is listed on the Nasdaq under the ticker symbol RNA. Atrium is classified as an emerging growth company and is headquartered in San Diego, California.
What the Filing Says
The amended filing clarifies, "This Form 8-K/A is being filed as an amendment to correct the previously disclosed number of shares outstanding after the offering. No other information has been revised." This statement emphasizes the company's commitment to accurate reporting.
Impact
This amendment may impact various stakeholders, including current and potential investors who rely on accurate data for decision-making. The correction ensures that investors have the correct information regarding the company's equity structure, which is vital for assessing the company's financial health and market position.
What's Next
The filing does not say what happens next.